 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1071103
Delivering Drugs by Inhalation
|
Description: |
Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions – aliments that require frequent drug administration for a protracted period of time.
The role of device design and development in defining and driving emerging opportunities in this sector cannot be overstated. Nebulizers, metered dose inhalers (MDIs), and dry powder inhalers (DPIs) have each found a niche in the quest for optimal treatment and convenient use. While nebulizers have evolved relatively independently of the drug formulations they deliver, the current generation of MDIs and DPIs have been developed or tailored for the specific pharmaceutical being delivered, resulting in improved performance.
Several of the emerging drug products covered in this report will have a significant impact in the therapeutic markets they target, improving patient compliance and effectively changing the way important illnesses and conditions are treated.
Feature Summary - Analyzes and evaluates inhaled drugs currently in development and assesses the market potential for existing and probable future products - Examines inhalation device technology for commercial and development-stage devices, and evaluates product technology issues and evolving market factors - Provides detailed assessments of targeted disease segments, forecast growth and market potential, and therapeutic options - Forecasts the impact of new and emerging inhaled drug therapeutics on healthcare markets and prescribing decisions to 2012 - Profiles Inhaled drug product market participants, their technology, product development activity, and business strategies - Evaluates the impact of economic, technology, and regulatory factors on inhaled drug companies and their alliance partners
Methodology - Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations. - Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations. - Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques. |
|
Contents: |
Executive Summary
Inhaled Drug Delivery Market Dynamics - Established Therapeutic Targets - Emerging Therapies - Demographics and Growth - Competing Technologies - Market Drivers - Factors Limiting Growth
Inhalation Technology & Product Development Factors - Drug Formulations - Formulation Technologies - Delivery Profiles and Risk Factors - Excipients and Release Profiles - Inhalation Device Design Factors - Dry Powder Inhalers - Metered Dose Inhalers - Nebulizers - Performance Factors - Bioavailability - Dose Reproducibility - Active Compound Stability - Combination Drug Inhalers - Testing and Packaging - Emerging Device Technologies
Inhalation Devices – Device Assessments and Product Strategies - Dry Powder inhalers - Commercial Devices - Discrete Dose Devices - Reservoir Devices - Proprietary Dosing Technologies - Development-stage DPI Devices - Market Data and Forecasts - Metered Dose Inhalers - Commercial Devices - Pressurized MDIs - Breath-actuated MDIs - Advanced Design MDIs - Recent Technology Developments - Market Data and Forecasts - Nebulizers - Commercial Devices - Compressed Air Nebulizers - Ultrasonic Nebulizers - Advanced Technology Nebulizers - Recent Developments - Market Data and Forecasts
Inhaled Drug Delivery - Evolving Therapies, Products and Players - Upper Respiratory Indications - Asthma - Therapeutic Segment Analysis - Competitive Landscape - Prescribing Trends and Growth Factors - Emerging Inhaled Therapies - COPD - Therapeutic Segment Analysis - Competitive Landscape - Prescribing Trends and Growth Factors - Emerging Inhaled Therapies - Systemic Drug Delivery - Alpha-1 Deficiency - Aerosolized AAT - Bioterror - Atropine - Ciprofloxacin - Cystic Fibrosis - Arikace - Aztreonam - Bronchitol - Ciprofloxacin - Denufosol - Heparin - Lancovutide - Levofloxacin - Tobramycin - Zysolin - Diabetes - Afresa - Endocrinology - hGH - Immune System Modulators - Cyclosporine - Infectious Diseases - Amikacin - Interferon-? - ALN-RSV01 - Vancomycin - Influenza - CS-8958 - Laninamivir - PUR003 - Zanamivir - Neurology - Insomnia - Zelaplon - Migraine - Dihydroergotamine - Loxapine - Prochlorperazine - Triptan Analog - Parkinson’s Disease - Apomorphine - Schizophrenia - Loxapine - Pulmonary Hypertension - Aironite - Ventavis/Iloprost - Treprostinil - Oncology - Cisplatin - Pain Management - Morphine - Fentanyl Product 1 - Fentanyl Product 2 - Fentanyl Product 3 - Sexual Health - Female Sexual Dysfunction - Apomorphine - Erectile Dysfunction - Apomorphine
Market Factors - Usability and Patient Preferences - Regulatory Issues - Patient Compliance - The Role of CMOs/CSOs
Company Profiles |
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/1071103
Order by Fax - using the order form below
Order By Post - print the order form below and send to
 |
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2 Printed 29/11/2009 02:40:12 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
Product Name: |
Delivering Drugs by Inhalation
|
|
Web Address: |
http://www.researchandmarkets.com/reports/1071103
|
|
Office Code: |
|
OC8HJNPOUMUXU
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Electronic (PDF)
- Single User
|
|
€1,914.00
|
|
Electronic (PDF)
- Site License
|
|
€2,586.00
|
|
Electronic (PDF)
- Enterprisewide
|
|
€3,694.00
|
Contact information
Please enter all the information below in BLOCK CAPITALS.
 |
|
First Name: |
Last Name: |
|
Email Address: |
 |
|
Job Title: |
 |
|
Organisation: |
 |
|
Address: |
 |
|
City: |
 |
|
Postal/Zip Code: |
 |
|
Country: |
 |
|
Phone Number: |
 |
|
Fax Number: |
 |
|
Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)
 |
Page 2 of 2 Printed 29/11/2009 02:40:12
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
American Express
|
|
Diners Club
|
|
Master Card
|
|
Visa
|
|
|
|
 |
|
Cardholder's Name: |
 |
|
|
|
Cardholder's Signature: |
 |
|
|
|
Expiry Date: |
/  |
|
|
|
Card Number: |
 |
|
|
|
CVV Security Code: |
 |
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
 |
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
 |
|
 |
Please transfer funds to:
 |
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
 |
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)
|
 |
 |
|
|